Our Pipeline
Our research focuses on clinically-derived psychedelic compounds that have shown significant promise in transforming patient outcomes in mental health. We believe these investigational compounds have the potential to become rapid-acting, durable, and scalable treatments for people living with difficult-to-treat mental health conditions
BPL-003
Mebufotenin benzoate
VLS-01
DMT
EMP-01
R-MDMA
Discovery
(Novel 5-HT2A Receptor Agonists incl. non-hallucinogenic neuroplastogens)
About BPL-003 (mebufotenin benzoate)
BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with treatment-resistant depression (TRD). Mebufotenin is also known as 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine and is a serotonergic neuromodulator. BPL-003 is being developed to produce rapid, robust and durable treatment effects from a single dose, within a two-hour interventional psychiatry treatment paradigm, and with a favourable safety profile.
Treatment involves administration of BPL-003 in a clinical setting, with preparation, monitoring and follow-up provided by healthcare professionals to support patients and ensure their safety.
BPL-003 has been designed to produce rapid, robust and durable treatment effects from a single dose, within a two-hour interventional psychiatry treatment paradigm.
BPL-003 has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration and is covered by granted US, UK and European composition-of-matter patents, with multiple further claims pending in various jurisdictions.
About VLS-01 (buccal film DMT)
VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with treatment-resistant depression (TRD).
Pharmacologically, VLS-01 is a partial to full agonist of the 5-HT1/2/6/7 sub-receptors and is being developed to potentially offer rapid, robust, and durable efficacy with a favorable safety profile. VLS-01 is designed to fit within the established two-hour interventional psychiatry treatment paradigm, positioning it for integration into existing care models.
AtaiBeckley is conducting Elumina, a multi-center, double-blind, randomized, placebo-controlled Phase 2 trial of VLS-01, which is designed to assess the efficacy, safety, and tolerability of repeated dosed of VLS-01 in adults with TRD. Topline data from Elumina is anticipated in the second half of 2026.
About EMP-01 (oral R-MDMA)
EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder (SAD).
AtaiBeckley is conducting an exploratory, randomized, double-blind, placebo-controlled Phase 2 study of EMP-01, which is designed to assess the safety, tolerability and efficacy of EMP-01 in adults with SAD. Topline data from the trial is anticipated in the first quarter of 2026.